IMV
IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.
3
Funding Rounds
$55.3m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| Br*** E. Lo** | - | - | - |
| Wa***** Ki***** | - | - | - |
| Name | Phone | Social networks | |
|---|---|---|---|
| Mi***** P. Ba**** | - | - | - |
| Ma**** Wa***** | - | - | |
| Ju*** Gr***** | - | - | - |
| Sh******* Ti**** | - | - | - |
| Ky** Ku******* | - | - | - |
| Br****** Da***** | - | - | - |
| Mi***** Ka*** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company IMV has raised a total of $55.35m in funding over 3 rounds.
Key Insights:
- IMV Funding Round, January 2022: $750k
- IMV Private equity, May 2020: $25.1m
- IMV Private equity, March 2019: $29.5m
IMV Funding Round, January 2022
$750k
IMV Private equity, May 2020
$25.1m
IMV Private equity, March 2019
$29.5m
Industries
IMV is active in the following industries:
- Vaccine
- Immunotherapy
- Biomedical engineering
- Biopharmaceutical
- Drug delivery
- Engineering
- Technology
- Biology
- Biotechnology
- Healthcare
- Cancer
- T cell
- Cell therapy
- CAR T-Cell therapy